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I read with considerable interest the epidemiological
study by Insawang et al., which demonstrates an associ-
ation between monosodium glutamate (MSG) intake
and the prevalence of the Metabolic Syndrome in a rural
Thai population [1]. It is important to point out that
Insawang et al. did not claim that MSG causes the
Metabolic Syndrome, they did however concluded that
“elevated dietary MSG consumption is significantly
associated with having the Metabolic Syndrome and
being overweight in a Thai rural population”.
The present commentary by Dr Rogers [2] concerning
the research by Insawang et al. stresses throughout that
there is no supporting evidence for a direct causal rela-
tionship between MSG intake and the prevalence of
Metabolic Syndrome and overweight. The relevance of
this oft-repeated statement is questionable since
Insawang et al. never proposed a direct causal relation-
ship between MSG intake and the Metabolic Syndrome.
Although the authors of this epidemiological study are
under no obligation to provide evidence for a causal re-
lationship, a number of issues were raised which make
interesting points for discussion. One concern broached
by Dr Rogers was that the authors failed to mention in
their Discussion a previous publication regarding the
Jiangsu Nutritional Study of 1227 Chinese adults [3],
which did not show an association between MSG and
obesity or weight gain over 5 years. In point of fact, theCorrespondence: kate@kfshrc.edu.sa
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reproduction in any medium, provided the ormethodology and the conclusions drawn from that par-
ticular study were not only questioned, but seriously
criticized [4]. Nevertheless, one of the reported findings
was a significant association between MSG intake in
2002 and waist circumference five years later [4]. Al-
though it is perhaps understandable that the authors
Insawang et al. did not comment on the lack of associ-
ation between MSG and body weight [3], they did dis-
cuss a separate publication concerning the exact same
population of 1227 Chinese adults, from the same
corresponding author, which showed a significant posi-
tive association between MSG intake and hypertension
[5]. Elevated blood pressure is one of the five conditions
which constitute the Metabolic Syndrome. The National
Cholesterol Education Program Adult Treatment Panel
III (NCEP) criteria require the presence of at least 3 of
the following [6]:
[1] Hypertension, defined as elevated blood pressure
defined as ≥ 130/85 mmHg.
[2] Abdominal obesity defined as waist circumference
≥ 102 cm or 40 inches (male), or ≥ 88 cm or 36
inches (female).
[3] Hyperglycemia, defined as elevated Fasting plasma
glucose ≥ 110 mg/dl.
[4] Dyslipidemia, defined as elevated triglycerides ≥
150mg/dL.
[5] Dyslipidemia, defined as presence of high-density
lipoprotein cholesterol (HDL-C) ≤ 40 mg/dL (male),
or ≤ 50 mg/dL (female).This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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criteria for the presence of the Metabolic Syndrome; and
indeed, animal model systems indicate that MSG-obese
rodents exhibit either lower body weights [7-10], or
similar body weights compared to control animals
[11,12], depending on the species and experimental
conditions. However, impaired cardiovascular autonomic
function, elevated arterial pressure, insulin resistance
and dyslipidemia have all been documented in rodents
exposed to MSG during the neonatal period at a time
when the blood brain barrier is immature and vulnerable
to excitotoxicity [13,14]. Moreover, neonatal exposure to
non-physiological levels of MSG is a proven experimen-
tal methodology for inducing Metabolic Syndrome in
rodents [15-18]; and sometimes referred to as “hypothal-
amic obesity” [19,20] due to the fact that high levels of
glutamate may damage the hypothalamus and other
areas of the brain which are rich in glutamate receptors
[11,12]. Interestingly, increased hypothalamic inflamma-
tory signaling and neuronal injury can also be induced
in rodents consuming high fat diets [21-24]; and recent
data also provides evidence of hypothalamic low-grade
inflammation and gliosis in obese humans [24,25], which
may impair the regulation of food intake and energy
expenditure.
Conclusion
[1] The authors of the epidemiological study associating
MSG consumption with the prevalence of Metabolic
Syndrome were under no obligation to provide a causal
relationship between the two. [2] Under experimental
conditions in rodents, non-physiological levels of MSG,
or high levels of dietary fat may promote damage to the
hypothalamus and other areas of the brain regulating en-
ergy expenditure. [3] In humans, obesity may be
associated with hypothalamic damage. The commentary
by Rogers has provided several interesting points of
discussion.
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